人类苏丹病毒病综述:流行病学、自然史与免疫学
2025年乌干达发生非洲第九次苏丹病毒(SUDV)疫情。本综述汇总1976年以来苏丹病毒病(SVD)的流行病学、自然史和免疫学证据。潜伏期平均约1周,典型表现为流感样疾病后出现严重腹泻病,常伴心肺症状和脱水。截至2022年合并病死率为49%(95%CI 39-58),2025年疫情记录病死率为29%。
要点
- SVD潜伏期平均约1周,典型表现为流感样症状后严重腹泻,可伴心肺症状和脱水。
- 截至2022年合并病死率49%(95%CI 39-58),2025年疫情病死率29%。
- 传播主要经密切接触急性症状期患者及其体液,驱动家庭和院内传播。
核心结论
- SVD是类似埃博拉病毒的丝状病毒所致严重发热性疾病,截至2022年合并病死率49%(95%CI 39-58),2025年疫情病死率29%。
- 早期T细胞反应和SUDV特异性抗体可能对存活重要,免疫抑制和失控炎症可能预测致死结局。
- 幸存者感染后可持续存在体液和细胞免疫长达15年。
研究设计与样本
- 综述汇总1976年以来苏丹病毒病暴发的流行病学、自然史和免疫学证据。
主要发现
- 潜伏期平均约1周,SVD典型表现为流感样疾病后严重腹泻病,常伴心肺症状和脱水。
- 临床发现可包括肾和肝损伤、急性炎症和凝血功能障碍,重症可快速进展至休克、多器官衰竭和死亡。
- 病毒从症状出现时即可在血液中检出,急性病程期间达峰。
- 传播主要经密切接触急性症状期个体及其体液,驱动家庭和院内传播。
- 幸存者感染后持久体液和细胞免疫可达15年。
关键数值与推荐
- 截至2022年合并病死率49%(95%CI 39-58)。
- 2025年疫情记录病死率29%。
- 潜伏期平均约1周。
临床怎么用
- 识别流感样症状后严重腹泻病且伴心肺症状和脱水者,结合急性期接触史考虑SVD。
- 从症状出现时即可检测血液中病毒,急性病程期间病毒载量达峰。
- 严控密切接触急性症状期患者及其体液的传播途径,防范家庭和院内传播。
局限性
- 迄今暴发虽提供有价值信息,但存在大量证据缺口和局限性。
- 未来疫情准备应包括前瞻性规划高质量研究以快速解决关键证据缺口。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In 2025, Uganda had Africa's ninth outbreak of disease caused by Sudan virus (SUDV), a filovirus similar to Ebola virus (EBOV) that causes severe febrile disease in humans. In this Review, we summarise the evidence on the epidemiology, natural history, and immunology of Sudan virus disease (SVD) from outbreaks since 1976. Following an incubation period averaging about 1 week, SVD typically presents with an influenza-like illness followed by a severe diarrhoeal disease, often accompanied by cardiorespiratory symptoms and dehydration. Clinical findings can include kidney and liver injury, acute inflammation, and coagulopathy. Severe cases can progress rapidly to shock, multiorgan failure, and death. The pooled case-fatality rate until 2022 was 49% (95% CI 39-58), although a lower case-fatality rate of 29% was recorded during the 2025 outbreak. The virus is detectable in blood from symptom onset, peaking during acute illness. Transmission occurs mainly through close contact with acutely symptomatic individuals and their body fluids, driving household and nosocomial spread. Early T-cell responses and SUDV-specific antibodies might be important for survival, and suppressed immunity and uncontrolled inflammation might predict fatal outcomes. Survivors present durable humoral and cellular immunity for up to 15 years after infection. Although outbreaks to date offer valuable insights into SVD, substantial evidence gaps and limitations exist. Future outbreak preparedness should include prospective planning for high-quality research that can be rapidly implemented to address key evidence gaps. Strengthening these data, together with advancing the development and evaluation of vaccines and therapeutics, will be essential for timely and effective outbreak response.
引用
- Whitworth HS, Meller M, Zaric M, et al. Sudan virus disease in humans. Lancet Glob Health. 2026. PMID: 42379200. doi:10.1016/S2214-109X(26)00072-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。